Security key
61023L108
- Security type / class
- Equity / COM
- Total 13F shares
- 418,162
- Total 13F value
- $310,094
- Share change
- +22,934
- SEC-reported price per share
- $0.73
- Number of holders
- 12
- Value change
- +$19,931
- Number of buys
- 6
- Number of sells
- 5
Report period
Q2 2024
Institutions
12
Top holders
10
MNPR full security history
Ownership snapshot
Full 13F holder table
Monopar Therapeutics SEC filings
Monopar Therapeutics company facts
Monopar Therapeutics 13D/G history
Broader feeds
Ownership snapshot
Top reported holders of MNPR - MONOPAR THERAPEUTICS INC - COM (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Michael J. Brown
Disclosed value leader
Michael J. Brown
Comparable rows
0/15
Latest evidence
31 Mar 2024
3/4/5
13F
Highest disclosed value: $136,941
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
Michael J. Brown has the largest disclosed position value at $136.9K.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Michael J. Brown's linked filing trail.
Disclosed position value
Top 5
Michael J. Brown
$136.9K
MILLENNIUM MANAGEMENT LLC
$131K
Andrew Paul Mazar
$94.4K
VANGUARD GROUP INC
$30.8K
GEODE CAPITAL MANAGEMENT, LLC
$28.1K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Michael J. Brown |
3/4/5
Director
|
—
denominator unverified
|
$136,941
402,530 shares
|
— | 31 Dec 2023 |
| MILLENNIUM MANAGEMENT LLC |
13F
Company
|
—
denominator unverified
|
$131,011
192,381 shares
|
— | 31 Mar 2024 |
| Andrew Paul Mazar |
3/4/5
Chief Scientific Officer, Director
|
—
mixed-class rows
|
$94,434
277,584 shares
mixed-class rows
|
— | 31 Mar 2022 |
| VANGUARD GROUP INC |
13F
Company
|
—
denominator unverified
|
$30,759
45,167 shares
|
— | 31 Mar 2024 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
—
denominator unverified
|
$28,056
41,199 shares
|
— | 31 Mar 2024 |
| HRT FINANCIAL LP |
13F
Company
|
—
denominator unverified
|
$21,000
32,113 shares
|
— | 31 Mar 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
12
Shares
418,162
Rows available
12
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
15
Q2 2024 holders
12
Holder diff
-3
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 value | Q2 2024 value | Value change | Value Chg % |
|---|